ICU Medical Inc
NASDAQ:ICUI

Watchlist Manager
ICU Medical Inc Logo
ICU Medical Inc
NASDAQ:ICUI
Watchlist
Price: 128.15 USD -1.86% Market Closed
Market Cap: $3.2B

EV/EBITDA

13.4
Current
5%
Cheaper
vs 3-y average of 14.1

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
13.4
=
Enterprise Value
$4B
/
EBITDA
$310.1m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
13.4
=
Enterprise Value
$4B
/
EBITDA
$310.1m

Valuation Scenarios

ICU Medical Inc is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (14.1), the stock would be worth $134.19 (5% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-4%
Maximum Upside
+32%
Average Upside
10%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 13.4 $128.15
0%
3-Year Average 14.1 $134.19
+5%
5-Year Average 17.7 $169.21
+32%
Industry Average 12.9 $122.96
-4%
Country Average 14.4 $136.99
+7%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$4B
/
Jan 2026
$310.1m
=
13.4
Current
$4B
/
Dec 2026
$426.3m
=
9.4
Forward
$4B
/
Dec 2027
$463.7m
=
8.6
Forward
$4B
/
Dec 2028
$510.3m
=
7.9
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
ICU Medical Inc
NASDAQ:ICUI
3.2B USD 13.4 4 322.1
US
Medline Inc
NASDAQ:MDLN
62.4B USD 0 0
JP
Hoya Corp
TSE:7741
9.8T JPY 28.4 39.1
CH
Alcon AG
SIX:ALC
30.5B CHF 14.9 38.9
DK
Coloplast A/S
CSE:COLO B
98.2B DKK 12.9 24.5
US
Align Technology Inc
NASDAQ:ALGN
13.9B USD 14.8 34
UK
ConvaTec Group PLC
LSE:CTEC
4.5B GBP 11.9 34.2
CA
Bausch + Lomb Corp
NYSE:BLCO
5.7B USD 16.9 -15.7
KR
HLB Inc
KOSDAQ:028300
8.3T KRW -83.8 -37.5
JP
Asahi Intecc Co Ltd
TSE:7747
895.2B JPY 23.9 50.6
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.3B USD 14.5 22.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
ICU Medical Inc
NASDAQ:ICUI
Average EV/EBITDA: 16.9
13.4
18%
0.7
US
M
Medline Inc
NASDAQ:MDLN
Not Available
9%
N/A
JP
Hoya Corp
TSE:7741
28.4
13%
2.2
CH
Alcon AG
SIX:ALC
14.9
9%
1.7
DK
Coloplast A/S
CSE:COLO B
12.9
6%
2.2
US
Align Technology Inc
NASDAQ:ALGN
14.8
14%
1.1
UK
ConvaTec Group PLC
LSE:CTEC
11.9
11%
1.1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.9
29%
0.6
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -83.8 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
23.9
13%
1.8
US
Lantheus Holdings Inc
NASDAQ:LNTH
14.5
23%
0.6
P/E Multiple
Earnings Growth PEG
US
ICU Medical Inc
NASDAQ:ICUI
Average P/E: 570.7
4 322.1
606%
7.1
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
39.1
15%
2.6
CH
Alcon AG
SIX:ALC
38.9
32%
1.2
DK
Coloplast A/S
CSE:COLO B
24.5
21%
1.2
US
Align Technology Inc
NASDAQ:ALGN
34
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
34.2
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.7 N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -37.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
50.6
40%
1.3
US
Lantheus Holdings Inc
NASDAQ:LNTH
22.6
30%
0.8

Market Distribution

In line with most companies in the United States of America
Percentile
47th
Based on 9 875 companies
47th percentile
13.4
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

ICU Medical Inc
Glance View

ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory. ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.

ICUI Intrinsic Value
150.3 USD
Undervaluation 15%
Intrinsic Value
Price $128.15
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett